Literature DB >> 21864292

Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases.

Aaron C Tyagi1, Utpal Sen, Paras K Mishra.   

Abstract

MicroRNAs ( miRNAs) are highly conserved, 19-23 nucleotide long, non-coding, endogenous RNA, which are transcribed from either intergenic, intronic or polycistronic regions and modulate gene expression through mRNA degradation or translational repression. They are fine tuners of biological processes and have recently emerged as biomarkers and therapeutic targets of cardiovascular diseases. Several miRNAs regulate stem cell for differentiation, proliferation and degeneration. Stem cells are pluripotent, self-renewing and clonogenic cells having tremendous potential for regenerative therapy. The current therapeutic approach is unable to cope up with rapidly increasing rates of diabetes and cardiovascular diseases. The empirical and clinical evidences revealed that transplantation of exogenous stem cells can regenerate beta cells in diabetic patients and myocardium in patients with myocardial infarction. Nevertheless, the major limitation of stem cell therapy is unpredictable behavior of exogenous stem cells that incur few reports of teratoma and cancer after transplantation. Therefore, understanding the regulation of newly transplanted stem cells into the foreign body is a major challenge to translational research / clinical trail. Since miRNA plays pivotal role in the fine regulation of proliferation and differentiation of stem cells, investigations on the regulation of miRNA in transplanted stem cells in a specific micro-environment that houses the stem cell is indispensable. Additionally, the inhibition or over expression of specific miRNAs in the niche surrounding the stem cell will be crucial for maintaining the specific lineage of exogenous stem cells. This review embodies major advancement in the field of miRNA biogenesis and its regulatory mechanisms, role of different miRNAs and stem cells as a therapeutic target for diabetes and cardiovascular diseases. It also provides insights into the novel future therapy, where synergistic approach for manipulating miRNAs and stem cells will emerged as a potential treatment for diabetes and cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864292     DOI: 10.2174/157339911797579179

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  13 in total

1.  Cardiac stem cell niche, MMP9, and culture and differentiation of embryonic stem cells.

Authors:  Paras Kumar Mishra; Nicholas John Kuypers; Shree Ram Singh; Noel Diaz Leiberh; Vishalakshi Chavali; Suresh C Tyagi
Journal:  Methods Mol Biol       Date:  2013

Review 2.  Cardiac matrix: a clue for future therapy.

Authors:  Paras Kumar Mishra; Srikanth Givvimani; Vishalakshi Chavali; Suresh C Tyagi
Journal:  Biochim Biophys Acta       Date:  2013-09-17

3.  Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts.

Authors:  Vishalakshi Chavali; Suresh C Tyagi; Paras Kumar Mishra
Journal:  Cell Biochem Biophys       Date:  2014-01       Impact factor: 2.194

4.  MicroRNA-9 inhibits hyperglycemia-induced pyroptosis in human ventricular cardiomyocytes by targeting ELAVL1.

Authors:  Prince Jeyabal; Rajarajan A Thandavarayan; Darukeshwara Joladarashi; Sahana Suresh Babu; Shashirekha Krishnamurthy; Arvind Bhimaraj; Keith A Youker; Raj Kishore; Prasanna Krishnamurthy
Journal:  Biochem Biophys Res Commun       Date:  2016-02-17       Impact factor: 3.575

5.  Induction of autophagy markers is associated with attenuation of miR-133a in diabetic heart failure patients undergoing mechanical unloading.

Authors:  Shyam Sundar Nandi; Michael J Duryee; Hamid R Shahshahan; Geoffrey M Thiele; Daniel R Anderson; Paras K Mishra
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

Review 6.  Stem Cell-Derived Exosomes, Autophagy, Extracellular Matrix Turnover, and miRNAs in Cardiac Regeneration during Stem Cell Therapy.

Authors:  Priyanka Prathipati; Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

7.  Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.

Authors:  Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

8.  Hydrogen sulfide mitigates homocysteine-mediated pathological remodeling by inducing miR-133a in cardiomyocytes.

Authors:  Varun Kesherwani; Shyam Sundar Nandi; Surender K Sharawat; Hamid R Shahshahan; Paras Kumar Mishra
Journal:  Mol Cell Biochem       Date:  2015-03-13       Impact factor: 3.396

9.  Oncostatin M-induced cardiomyocyte dedifferentiation regulates the progression of diabetic cardiomyopathy through B-Raf/Mek/Erk signaling pathway.

Authors:  Xiaotian Zhang; Sai Ma; Ran Zhang; Shuang Li; Di Zhu; Dong Han; Xiujuan Li; Congye Li; Wei Yan; Dongdong Sun; Bin Xu; Yabin Wang; Feng Cao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-01       Impact factor: 3.848

10.  Predictors and prevention of diabetic cardiomyopathy.

Authors:  Vishalakshi Chavali; Suresh C Tyagi; Paras K Mishra
Journal:  Diabetes Metab Syndr Obes       Date:  2013-04-11       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.